Efficacy and Treatment-Related Adverse Events of Romidepsin in PTCL Clinical Studies: A Systematic Review and Meta-Analysis

Background: Peripheral T-cell lymphoma (PTCL) is an extensive class of biologically and clinically heterogeneous diseases with dismal outcomes. The histone deacetylase inhibitor (HDACi) romidepsin was approved for relapsed and refractory (R/R-PTCL) in 2011. This meta-analysis was performed to assess...

Full description

Bibliographic Details
Main Authors: Jun Du, Xinle Han, Suwen Lin, Chen Qiu, Lijun Zhu, Zoufang Huang, Jian Hou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-11-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2021.732727/full